{"id":"casirivimab-and-imdevimab-drug-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL4650248","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Casirivimab and imdevimab are two recombinant human monoclonal antibodies that bind to non-overlapping epitopes on the SARS-CoV-2 spike protein receptor-binding domain. By simultaneously targeting the spike protein, they prevent viral attachment to the ACE2 receptor and neutralize the virus, reducing viral load and infection severity. The dual-antibody approach reduces the risk of viral escape mutants.","oneSentence":"This monoclonal antibody combination blocks the SARS-CoV-2 spike protein, preventing viral attachment and entry into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:10.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease)"}]},"trialDetails":[{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT05195060","phase":"","title":"TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-12-14","conditions":"COVID-19","enrollment":1178},{"nctId":"NCT05081388","phase":"PHASE1, PHASE2","title":"COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-08","conditions":"SARS-CoV-2","enrollment":25},{"nctId":"NCT05074433","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-10-25","conditions":"Immunocompromised","enrollment":66},{"nctId":"NCT04992273","phase":"PHASE2","title":"COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-09-13","conditions":"COVID-19","enrollment":7},{"nctId":"NCT04852978","phase":"PHASE2","title":"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-29","conditions":"Healthy, Chronic Stable Illness","enrollment":295},{"nctId":"NCT05092581","phase":"PHASE1","title":"COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-12-16","conditions":"COVID-19","enrollment":2},{"nctId":"NCT05181683","phase":"PHASE1","title":"COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-01-07","conditions":"Healthy, Chronic Stable Illness","enrollment":45},{"nctId":"NCT05013632","phase":"","title":"COVID-19 International Drug Pregnancy Registry","status":"RECRUITING","sponsor":"Pregistry","startDate":"2021-12-01","conditions":"Covid19","enrollment":2000},{"nctId":"NCT05268601","phase":"","title":"COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2021-10-14","conditions":"COVID-19","enrollment":251},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT06233357","phase":"","title":"Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2021-08-01","conditions":"COVID-19, Outcome, Fatal, Tocilizumab","enrollment":95},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04425629","phase":"PHASE3","title":"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-16","conditions":"COVID-19","enrollment":10078},{"nctId":"NCT04617535","phase":"","title":"Compassionate Use of REGN-COV2 for the Treatment of COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05502081","phase":"PHASE4","title":"Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients","status":"COMPLETED","sponsor":"Mansoura University Hospital","startDate":"2022-09-02","conditions":"COVID-19","enrollment":265},{"nctId":"NCT04452318","phase":"PHASE3","title":"COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-13","conditions":"Healthy Participants","enrollment":3303},{"nctId":"NCT04426695","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-10","conditions":"COVID-19","enrollment":2252},{"nctId":"NCT05205759","phase":"PHASE3","title":"Non-inferiority Trial on Monoclonal Antibodies in COVID-19","status":"TERMINATED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-12-09","conditions":"COVID-19","enrollment":319},{"nctId":"NCT05157997","phase":"PHASE1","title":"Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2022-01","conditions":"COVID-19, Organ Transplant","enrollment":""},{"nctId":"NCT04666441","phase":"PHASE2","title":"COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-15","conditions":"COVID-19","enrollment":1149},{"nctId":"NCT04519437","phase":"PHASE1","title":"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-26","conditions":"Healthy, Chronic Stable Illness","enrollment":974}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["REGN-COV2"],"phase":"marketed","status":"active","brandName":"Casirivimab and Imdevimab Drug Combination","genericName":"Casirivimab and Imdevimab Drug Combination","companyName":"Mansoura University Hospital","companyId":"mansoura-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This monoclonal antibody combination blocks the SARS-CoV-2 spike protein, preventing viral attachment and entry into host cells. Used for COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}